---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-006657"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T16:42:22.017923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing

## Summary
- Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.
- Six-month net loss $8.95M ($0.66/shr) vs $4.90M ($0.45/shr); raised ~$11.6M via ATM and direct investment.
- Working capital $14.66M; cash and equivalents $15.89M at quarter end.
- Phase 3 ARDS trial >25% randomized; approvals in Canada, Poland, Colombia; U.S. design discussions ongoing.
- Phase 2b allergic contact dermatitis study 75% enrolled; completion expected Q4 2022, topline data early 2023.

## SEC filing metadata
- accession: 0001654954-22-006657
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/0001654954-22-006657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/edsa_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-006657
- JSON: https://secwatch.observer/filing/0001654954-22-006657.json
- Plain text: https://secwatch.observer/filing/0001654954-22-006657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.